ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Measures of Success

Jason Liebowitz, MD, FACR  |  September 24, 2024

Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherGuidanceMeeting Reports Tagged with:APLARAPLAR 2024AS Resource CenterAsia Pacific League of Associations for Rheumatology (APLAR)axial spondyloarthritis (SpA)Diagnosisspondyloarthritis (SpA)Treat-to-Target

Don’t Be Afraid to Engage: Health Technologies for Patients & Rheumatologists

Jason Liebowitz, MD, FACR  |  September 24, 2024

Symptom checkers, telehealth and more—here are insights into the effects new technologies are having on rheumatology.

Filed under:Meeting ReportsPractice SupportTechnology Tagged with:APLARAPLAR 2024appsAsia Pacific League of Associations for Rheumatology (APLAR)Personalized medicineTechnologytelehealthtelemedicine

Plan Ahead: Clinical Tips for Managing Reproductive Health in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 24, 2024

Dr. May Ching Soh highlighted practical approaches when caring for pregnant patients with rheumatic disease.

Filed under:ConditionsMeeting Reports Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)pregnancypregnancy complicationspregnant women

FDA Accepts New Drug Application for Suzetrigine, a Non-Opioid Analgesic

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2024

The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.

Filed under:AnalgesicsConditionsDrug UpdatesSoft Tissue Pain Tagged with:acute painFDAneuropathypost-surgerysuzetrigineU.S. Food and Drug Administration (FDA)VX-548

Ethics Forum: The ACR Code in Practice

Prajakta Masurkar, PhD, MPharm, & Charis Meng, MD  |  September 9, 2024

Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…

Filed under:EthicsGuidancePractice Support Tagged with:ACR Code of EthicsEthics Forum

Get Excited for ACR Convergence 2024

From the College  |  September 9, 2024

An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2024

Case Report: Leprosy Masquerading as Relapsing Polychondritis

Rohan Goel, MBBS, MD, Rashmi Roongta, MBBS, MD, DM, Dipendranath Ghosh, MBBS, MD, DM, & Parasar Ghosh, MD, DM  |  September 9, 2024

Autoimmune rheumatic diseases (AIRDs) are known for their systemic presentations and multi-organ involvement. Numerous infectious diseases, particularly mycobacterial, fungal and indolent bacterial infections endemic to specific geographic regions, present with varied signs and symptoms of multi-system involvement and can mimic AIRDs. Thus, differentiating infection from an AIRD is critical to resolve competing treatment approaches. This…

Filed under:Conditions Tagged with:case reportInfectionleprosymimicsrelapsing polychondritis

Role Reversal: When the Doctor Becomes a Patient

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  September 8, 2024

It was like a reverse Uno card had been thrown onto the table. My patient was now asking his rheumatologist, “Are you okay? You look like you’re in a lot of pain.” He was right. I was wincing trying to get up from my seat and limping trying to get a few steps over to…

Filed under:OpinionPatient PerspectiveRheuminations Tagged with:Rheumatic Disease Awareness MonthRheumatic Disease Awareness Month (RDAM)

How the ACR Helps with Reimbursement, Utilization Management & Other Practice Challenges

Carina Stanton  |  September 6, 2024

Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.

Filed under:InsurancePractice Support Tagged with:ACR advocacyACR Insurance Subcommittee (ISC)Member benefits

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2024

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDAFDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)PsAPsA Resource Centerpsoriatic arthritisU.S. Food and Drug Administration (FDA)upadacitinib

  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 249
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences